Leerink Partnrs Issues Negative Estimate for BSX Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings estimate for Boston Scientific from $0.71 to $0.70 per share, maintaining a "Strong-Buy" rating on the stock.
• Boston Scientific reported Q2 earnings of $0.75 per share, exceeding expectations and marking a 22.8% year-over-year revenue increase.
• Several analysts have recently raised their price targets for Boston Scientific, with targets reaching up to $135.00, indicating strong growth potential in the stock.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Leerink Partnrs dropped their Q3 2025 earnings estimates for Boston Scientific in a report released on Wednesday, October 1st. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will earn $0.70 per share for the quarter, down from their previous estimate of $0.71. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's Q1 2026 earnings at $0.78 EPS, Q3 2026 earnings at $0.87 EPS, Q4 2026 earnings at $0.95 EPS and FY2026 earnings at $3.46 EPS.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the firm earned $0.62 earnings per share. Boston Scientific's revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

Other equities analysts also recently issued research reports about the stock. Raymond James Financial raised their target price on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the company a "buy" rating in a research report on Wednesday. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Needham & Company LLC reiterated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Wednesday. Finally, UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $120.67.

Boston Scientific Price Performance

BSX stock opened at $95.78 on Thursday. Boston Scientific has a 1 year low of $80.64 and a 1 year high of $109.50. The firm has a 50-day moving average of $103.30 and a 200 day moving average of $102.08. The company has a market cap of $141.91 billion, a P/E ratio of 57.01, a PEG ratio of 2.35 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Insiders Place Their Bets

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock valued at $3,167,000 after acquiring an additional 3,932 shares in the last quarter. Bank of New Hampshire boosted its stake in Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock valued at $2,119,000 after acquiring an additional 16,699 shares in the last quarter. NS Partners Ltd boosted its stake in Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after acquiring an additional 5,704 shares in the last quarter. MRA Advisory Group acquired a new stake in Boston Scientific in the second quarter valued at approximately $273,000. Finally, Neville Rodie & Shaw Inc. raised its holdings in shares of Boston Scientific by 95.9% in the second quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider's stock worth $4,883,000 after buying an additional 22,255 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.